# Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection

> **NCT03991780** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Imperial College London** · enrollment: 8 (actual)

## Conditions studied

- Renal Transplant Rejection

## Interventions

- **DRUG:** Fostamatinib

## Key facts

- **NCT ID:** NCT03991780
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-05-08
- **Primary completion:** 2023-04-05
- **Final completion:** 2025-10-15
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03991780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03991780, "Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03991780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*